**Core Concept**
Pegylated Filgrastim is a long-acting glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of white blood cells, particularly neutrophils, in patients undergoing chemotherapy or hematopoietic stem cell transplantation. This medication is crucial in preventing neutropenia and its associated complications.

**Why the Correct Answer is Right**
Pegylated Filgrastim works by binding to the G-CSF receptor on the surface of bone marrow cells, stimulating the production and release of neutrophils into the bloodstream. By increasing neutrophil counts, Pegylated Filgrastim reduces the risk of infections, febrile neutropenia, and other complications associated with chemotherapy-induced neutropenia. This mechanism is particularly beneficial for patients undergoing high-dose chemotherapy, where the risk of neutropenia is significantly increased.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as Pegylated Filgrastim is not primarily used for the treatment of anemia. Anemia is typically managed with erythropoiesis-stimulating agents (ESAs) such as epoetin alfa or darbepoetin alfa.
**Option B:** This option is incorrect as Pegylastim is not used for the treatment of thrombocytopenia. Thrombocytopenia is typically managed with thrombopoietin receptor agonists (TPO-RAs) such as romiplostim or eltrombopag.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that Pegylated Filgrastim is a long-acting formulation, allowing for less frequent dosing compared to non-pegylated G-CSF analogs. This characteristic makes it a convenient option for patients requiring prolonged periods of neutrophil support.

**Correct Answer:** C.